RNA-seq confirmed selective amplification of the KRASG13D mutant allele (Supplementary Fig. 8a) and revealed a reduction in the wild-type KRAS allele; this may relate to a tumour-suppressor function for wild-type RAS36–39. Here, KRAS is linked to neoplasm.